We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Instrument Earnings Slated on Oct 27: TMO, ABMD, TFX
Read MoreHide Full Article
The S&P 500 index is so far off to a pretty good start to Q3, with earnings growth reaching the positive territory for the first time after five straight quarters of decline. With majority of the members yet to release their quarterly reports, we are definitely bullish about the gloomy equity market scenario demonstrating a change in trend by the end of the earnings season.
Medical, one of the 16 broader Zacks sectors is absolutely no exception to this trend improvement. The aggregate growth pace of this sector is gradually picking up stream with more and more companies coming up with their earnings reports. As per our latest Earnings Trends report, the sector is expected to deliver 3.7% earnings growth on the back of 7.4% higher revenues in the third quarter. So far, 11.3% of the members from this sector have released their quarterly reports, with earnings and revenue beat standing at impressive levels of 83.3% and 50%, respectively.
What’s in Store for the Med-Instrument Space?
Medical instrument, an important part of the medical device subcategory within the broader Medical sector, holds a lot of promise at the moment. According to a survey by KPMG, the companies under this category that expect to spend more than 6% of revenue on R&D/innovation is rising and fast exceeding the number of companies spending on R&Ds in other manufacturing industries. These innovations and breakthroughs can be of various forms – new products or surgical techniques or cost-effective products targeting the emerging markets.
Let’s take a look at the major Medical Instrument stocks slated to release their quarterly reports on Oct 27:
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. We are looking forward to Thermo Fisher’s recently completed colossal $4.2 billion acquisition of FEI Company. The buyout will significantly aid the company’s performance in life-science research. We also await the integration and expected synergy of Affimetrix, another mega acquisition by Thermo Fisher, expected to boost its offering in the fast-growing flow cytometry market.
Thermo Fisher is scheduled to report its third-quarter 2016 numbers on Oct 27. However, our proven model does not conclusively show that the company is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here.
Thermo Fisher currently has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at -$1.97. We also note that Thermo Fisher’s trailing 12-month earnings surprise came in at a negative 1.50%. The company carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Headquartered in Danvers, MA, Abiomed is engaged in developing, manufacturing and marketing medical products, designed to assist or replace the pumping function of the failing heart. We are upbeat about the fact that Abiomed’s Impella utilization is accelerating at a remarkable pace with an increasing number of hospitals and customer sites purchasing the same. We believe that the flagship Impella product line is a significant growth catalyst for the company.
Abiomed is slated to report its second-quarter fiscal 2017 numbers on Oct 27. While a favorable Zacks Rank #1 increases the predictive power of the ESP, a 0.00% ESP makes surprise prediction difficult. We note that in the last reported fiscal first quarter, the company registered an earnings beat of 31.82% and its trailing 12-month average surprise came in at a negative 34.92%.
This is a provider of single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It has a wide range of solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Teleflex is scheduled to report its third-quarter 2016 numbers on Oct 27. We expect the company to beat our third-quarter earnings estimates as it has a favorable combination of a Zacks Rank #3 and an Earnings ESP of +0.56%. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medical Instrument Earnings Slated on Oct 27: TMO, ABMD, TFX
The S&P 500 index is so far off to a pretty good start to Q3, with earnings growth reaching the positive territory for the first time after five straight quarters of decline. With majority of the members yet to release their quarterly reports, we are definitely bullish about the gloomy equity market scenario demonstrating a change in trend by the end of the earnings season.
Medical, one of the 16 broader Zacks sectors is absolutely no exception to this trend improvement. The aggregate growth pace of this sector is gradually picking up stream with more and more companies coming up with their earnings reports. As per our latest Earnings Trends report, the sector is expected to deliver 3.7% earnings growth on the back of 7.4% higher revenues in the third quarter. So far, 11.3% of the members from this sector have released their quarterly reports, with earnings and revenue beat standing at impressive levels of 83.3% and 50%, respectively.
What’s in Store for the Med-Instrument Space?
Medical instrument, an important part of the medical device subcategory within the broader Medical sector, holds a lot of promise at the moment. According to a survey by KPMG, the companies under this category that expect to spend more than 6% of revenue on R&D/innovation is rising and fast exceeding the number of companies spending on R&Ds in other manufacturing industries. These innovations and breakthroughs can be of various forms – new products or surgical techniques or cost-effective products targeting the emerging markets.
Let’s take a look at the major Medical Instrument stocks slated to release their quarterly reports on Oct 27:
Thermo Fisher Scientific, Inc. (TMO - Free Report)
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. We are looking forward to Thermo Fisher’s recently completed colossal $4.2 billion acquisition of FEI Company. The buyout will significantly aid the company’s performance in life-science research. We also await the integration and expected synergy of Affimetrix, another mega acquisition by Thermo Fisher, expected to boost its offering in the fast-growing flow cytometry market.
Thermo Fisher is scheduled to report its third-quarter 2016 numbers on Oct 27. However, our proven model does not conclusively show that the company is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here.
Thermo Fisher currently has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at -$1.97. We also note that Thermo Fisher’s trailing 12-month earnings surprise came in at a negative 1.50%. The company carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
THERMO FISHER Price and EPS Surprise
THERMO FISHER Price and EPS Surprise | THERMO FISHER Quote
ABIOMED, Inc.
Headquartered in Danvers, MA, Abiomed is engaged in developing, manufacturing and marketing medical products, designed to assist or replace the pumping function of the failing heart. We are upbeat about the fact that Abiomed’s Impella utilization is accelerating at a remarkable pace with an increasing number of hospitals and customer sites purchasing the same. We believe that the flagship Impella product line is a significant growth catalyst for the company.
Abiomed is slated to report its second-quarter fiscal 2017 numbers on Oct 27. While a favorable Zacks Rank #1 increases the predictive power of the ESP, a 0.00% ESP makes surprise prediction difficult. We note that in the last reported fiscal first quarter, the company registered an earnings beat of 31.82% and its trailing 12-month average surprise came in at a negative 34.92%.
ABIOMED INC Price and EPS Surprise
ABIOMED INC Price and EPS Surprise | ABIOMED INC Quote
Teleflex Incorporated (TFX - Free Report)
This is a provider of single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It has a wide range of solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Teleflex is scheduled to report its third-quarter 2016 numbers on Oct 27. We expect the company to beat our third-quarter earnings estimates as it has a favorable combination of a Zacks Rank #3 and an Earnings ESP of +0.56%. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
TELEFLEX INC Price and EPS Surprise
TELEFLEX INC Price and EPS Surprise | TELEFLEX INC Quote
Zacks' Best Investment Ideas for Long-Term Profit
Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>